Ray Therapeutics Closes $6M Seed Financing to Advance Novel Optogenetics Platform to Treat Blinding Diseases
Retrieved on:
Tuesday, January 4, 2022
Science, Other Science, Research, Pharmaceutical, Optical, Health, FDA, Clinical Trials, Severe cognitive impairment, Therapy, Retina, Optogenetics, Retinitis pigmentosa, Retinal ganglion cell, Neuron, Field line, Patient, CA, Ophthalmology, Prevalence, CEO, Person, RGC, Partner (business rank), Nyctalopia, Retinal degeneration, Central retinal artery occlusion, Light, Visual acuity, B cell, Pharmaceutical industry, Medical imaging, RP, Retinitis Pigmentosa, Ray Therapeutics, RETINITIS PIGMENTOSA, RAY THERAPEUTICS
Ray Therapeutics , a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.
Key Points:
- Ray Therapeutics , a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.
- Were excited to invest in Ray Therapeutics, which is developing a ground-breaking new approach to treat inherited retinal diseases using the power of optogenetics, Dmitry Kuzmin, Managing Partner, 4BIO Capital.
- This seed financing round led by top-tier advanced therapies investor 4BIO Capital, enables us to advance our optogenetic gene therapy platform, pipeline and people, said Paul Bresge, CEO & Co-Founder, Ray Therapeutics.
- Ray Therapeutics is developing novel optogenetics gene therapies for patients with blinding diseases.